Patents by Inventor Abbot Clark

Abbot Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080107644
    Abstract: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 binding to vitronectin. In another embodiment, the invention concerns a method of manufacturing a compound to be used as a treatment for glaucoma or elevated IOP comprising providing a candidate substance suspected of modulating PAI-1 binding, selecting the compound by assessing the ability of the candidate substance to decrease the amount of active PAI-1 in the trabecular meshwork of a subject suffering from glaucoma or elevated PAI-1, and manufacturing the selected compound.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Debra FLEENOR, Iok-Hou PANG, Abbot CLARK
  • Publication number: 20080085878
    Abstract: The present invention concerns a method for diagnosing or monitoring elevated intraocular pressure or glaucoma in a patient comprising providing a biological sample from the patient and measuring the expression level of a superoxide dismutase-2 (SOD-2) gene in the biological sample. The present invention also concerns methods for treating glaucoma or elevated intraocular pressure in a patient comprising administering to a patient an effective amount of an agent that modulates SOD-2 expression or SOD-2 activity.
    Type: Application
    Filed: February 28, 2007
    Publication date: April 10, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Wan-Heng WANG, Loretta McNatt, Abbot CLARK, Peter KLIMKO
  • Publication number: 20080051361
    Abstract: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: August 24, 2007
    Publication date: February 28, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Jon Chatterton, Abbot Clark
  • Publication number: 20070225263
    Abstract: The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal and optic nerve damage associated with glaucoma.
    Type: Application
    Filed: May 29, 2007
    Publication date: September 27, 2007
    Inventors: Iok-Hou Pang, Abbot Clark
  • Publication number: 20070208043
    Abstract: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.
    Type: Application
    Filed: December 22, 2006
    Publication date: September 6, 2007
    Applicant: ALCON, INC.
    Inventors: Abbot Clark, Wan-Heng Wang, Loretta McNatt
  • Publication number: 20070149473
    Abstract: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, Abbot Clark
  • Publication number: 20070149616
    Abstract: The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD as a result of having the Y402H polymorphism or other at risk variants in the complement factor H gene.
    Type: Application
    Filed: December 21, 2006
    Publication date: June 28, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Abbot Clark, Allan Shepard
  • Publication number: 20070142376
    Abstract: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
    Type: Application
    Filed: December 15, 2006
    Publication date: June 21, 2007
    Applicant: ALCON, INC.
    Inventors: Debra FLEENOR, Iok-Hou PANG, Allan SHEPARD, Mark HELLBERG, Abbot CLARK, Peter KLIMKO
  • Publication number: 20060275797
    Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one agent that inhibits binding and/or signaling of connective tissue growth factor (CTGF) via the TrkA/p75NTR receptor complex.
    Type: Application
    Filed: March 20, 2006
    Publication date: December 7, 2006
    Inventors: Allan Shepard, Nasreen Jacobson, Abbot Clark
  • Publication number: 20060223773
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: March 10, 2006
    Publication date: October 5, 2006
    Applicant: Alcon, Inc.
    Inventors: Abbot Clark, Wan-Heng Wang, Loretta McNatt, Jon Chatterton
  • Publication number: 20060216732
    Abstract: Methods and compositions for diagnosing and treating glaucoma are disclosed.
    Type: Application
    Filed: January 6, 2006
    Publication date: September 28, 2006
    Inventors: Abbot Clark, John Fingert, Loretta McNatt, Edwin Stone, Wan-Heng Wang
  • Publication number: 20060172961
    Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.
    Type: Application
    Filed: December 19, 2005
    Publication date: August 3, 2006
    Applicant: Alcon, Inc.
    Inventors: Abbot Clark, Wan-Heng Wang, Loretta McNatt
  • Publication number: 20060172965
    Abstract: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; ?1- and ?2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 3, 2006
    Applicant: Alcon, Inc.
    Inventors: Allan Shepard, Jon Chatterton, Abbot Clark, Martin Wax
  • Publication number: 20060172963
    Abstract: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; ?1- and ?2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 3, 2006
    Applicant: Alcon, Inc.
    Inventors: Allan Shepard, Jon Chatterton, Abbot Clark
  • Publication number: 20060154981
    Abstract: The use of 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular hypertension and glaucoma is disclosed.
    Type: Application
    Filed: January 12, 2006
    Publication date: July 13, 2006
    Inventors: Peter Klimko, Mark Hellberg, Wan-Heng Wang, Abbot Clark, Loretta McNatt
  • Publication number: 20060154910
    Abstract: Methods and compositions for treating retinal edema and NPDR are disclosed.
    Type: Application
    Filed: February 4, 2004
    Publication date: July 13, 2006
    Inventors: David Bingaman, Abbot Clark, Rajni Jani, Stella Robertson
  • Publication number: 20060142379
    Abstract: Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed.
    Type: Application
    Filed: February 14, 2006
    Publication date: June 29, 2006
    Inventors: Debra Shade, Iok-Hou Pang, Abbot Clark
  • Publication number: 20060134171
    Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of FPR.
    Type: Application
    Filed: December 1, 2005
    Publication date: June 22, 2006
    Inventors: Loretta McNatt, Wan-Heng Wang, Abbot Clark
  • Publication number: 20060134172
    Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL).
    Type: Application
    Filed: December 5, 2005
    Publication date: June 22, 2006
    Inventors: Allan Shepard, Abbot Clark, Mark Hellberg
  • Publication number: 20060094753
    Abstract: Compositions and methods for the treatment of glaucoma and other ocular diseases are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK), such as SP600125 in the treatment of glaucoma and other ocular diseases.
    Type: Application
    Filed: October 26, 2005
    Publication date: May 4, 2006
    Inventors: Iok-Hou Pang, Abbot Clark